Androgen-Deprivation Therapeutic Drugs has 6 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Mitapivat, Infliximab-Dyyb, Pazopanib. Patients taking Androgen-Deprivation Therapeutic Drugs should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 6
- Contraindicated
- 1
- Major
- 2
- Moderate
- 3
Contraindicated (1)
- Androgen-Deprivation Therapeutic Drugs + Mitapivat— PYRUKYND may affect CYP2B6 substrates with narrow therapeutic index. Avoid concomitant use.
Major (2)
- Androgen-Deprivation Therapeutic Drugs + Infliximab-Dyyb— Therapeutic infectious agents not recommended concurrently with infliximab due to increased infection risk.
- Androgen-Deprivation Therapeutic Drugs + Pazopanib— Coadministration may inhibit metabolism and cause serious adverse reactions. Not recommended.
Moderate (3)
- Androgen-Deprivation Therapeutic Drugs + Cefdinir— Concomitant administration reduces extent of cefdinir absorption by approximately 80%. Should be taken at least 2 hours …
- Androgen-Deprivation Therapeutic Drugs + Choline C-11— Androgen-deprivation therapy may interfere with 11C-choline PET imaging performance. Impact depends on hormonal responsi…
- Androgen-Deprivation Therapeutic Drugs + Ustekinumab-Auub— Ustekinumab may normalize CYP450 enzyme formation upon initiation or discontinuation; monitor therapeutic effect and adj…